Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development (Q34204623)

31 July 2017

Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development (English)

1 reference

31 July 2017

3

Osterhaus AD

1 reference

31 July 2017

Brandenburg AH

1

1 reference

PubMed ID

11282187

31 July 2017

Neijens HJ

series ordinal

2

1 reference

PubMed ID

11282187

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

31 July 2017

1 reference

31 July 2017

19

1 reference

31 July 2017

20-22

1 reference

31 July 2017

2769-2782

1 reference

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Duration of hospitalization in previously well infants with respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Epidemiology of respiratory viral infection among paediatric inpatients over a six-year period in north-east England

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Epidemiology of acute lower respiratory disease in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Polypeptides of pneumonia virus of mice. II. Characterization of the glycoproteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Characterization of the 10 proteins of human respiratory syncytial virus: identification of a fourth envelope-associated protein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Two distinct subtypes of human respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Antigenic variation between human respiratory syncytial virus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Antigenic and genomic diversity within group A respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Evolution of subgroup A respiratory syncytial virus: evidence for progressive accumulation of amino acid changes in the attachment protein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Concurrent circulation of antigenically distinct strains of respiratory syncytial virus during community outbreaks

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981-1986.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Occurrence of respiratory syncytial virus subtypes A and B strains in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Restriction pattern variability of respiratory syncytial virus during three consecutive epidemics in Denmark.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus associated with acute respiratory infections in Trinidadian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Animal models of respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Modes of transmission of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Immunity to and frequency of reinfection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial viral infection in infants with congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial viral infection in children with compromised immune function

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus infection in immunocompromised adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus or influenza?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Risk factors for mechanical ventilation in respiratory syncytial virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Clinical profile of pediatric patients hospitalized with respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus. An outbreak of acute respiratory illnesses in a home for infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Severity of respiratory syncytial virus infection is related to virus strain

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Relationship between clinical severity of respiratory syncytial virus infection and subtype

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus (RSV) bronchiolitis: comparative study of RSV groups A and B infected children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Severity of respiratory syncytial virus disease related to type and genotype of virus and to cytokine values in nasopharyngeal secretions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus genotypes and disease severity among children in hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

G protein variation in respiratory syncytial virus group A does not correlate with clinical severity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Local variability in respiratory syncytial virus disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Hospitalizations for respiratory syncytial virus infection in Alaska Native children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Relationship of parental smoking to wheezing and nonwheezing lower respiratory tract illnesses in infancy. Group Health Medical Associates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Diminished lung function as a predisposing factor for wheezing respiratory illness in infants.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Antibodies to respiratory syncytial virus polypeptides and their significance in human infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Immunoblot analysis of the human antibody response to respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Antibody response to respiratory syncytial virus structural proteins in children with acute respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

The Immunologic Response to Infection with Respiratory Syncytial Virus in Infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Specific human cytotoxic T cells recognize B-cell lines persistently infected with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Recognition of respiratory syncytial virus fusion protein by mouse cytotoxic T cell clones and a human cytotoxic T cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Cytokine response to respiratory syncytial virus stimulation of human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Increased number of T cells committed to IL-5 production after respiratory syncytial virus (RSV) infection of human mononuclear cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Different patterns of cytokine induction in cultures of respiratory syncytial (RS) virus-specific human TH cell lines following stimulation with RS virus and RS virus proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Speculation on Pathogenesis in Death from Respiratory Syncytial Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Detection of respiratory syncytial virus RNA in blood of neonates by polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus infection of human mononuclear leukocytes in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Maturation of human neonatal CD4+ and CD8+ T lymphocytes into Th1/Th2 effectors.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Immunological responses to respiratory syncytial virus infection in infancy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Peripheral blood cytokine responses and disease severity in respiratory syncytial virus bronchiolitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Determinants and kinetics of cytokine expression patterns in lungs of vaccinated mice challenged with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Immunity and immunopathology to respiratory syncytial virus. The mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Respiratory syncytial virus infections in human beings and in cattle

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

The efficacy of modified-live bovine respiratory syncytial virus vaccines in experimentally infected calves

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Interferon gamma production during bovine respiratory syncytial virus (BRSV) infection is diminished in calves vaccinated with formalin-inactivated BRSV.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Immune response of calves experimentally infected with non-cell-culture-passaged bovine respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Contribution of advances in immunology to vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Maternal immunization against viral disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Maternal immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for va

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Identification of mutations contributing to the reduced virulence of a modified strain of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

DNA vaccines: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Protection against respiratory syncytial virus infection by DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Nonreplicating vaccinia vector efficiently expresses recombinant genes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900536-3

7 January 2021

10.1016/S0264-410X(00)00536-3

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11282187